title: Tissue plasminogen activator in refractory unstable angina. A randomized double-blind placebo-controlled trial in patients with refractory unstable angina and subsequent angioplasty.
abstract: To evaluate the effect of recombinant tissue plasminogen activator (alteplase) on the clinical course, angiographic changes and the outcome of subsequent coronary angioplasty, 36 patients with angina at rest, despite bedrest and medical treatment including heparin, and with concomitant ECG changes, were studied. After diagnostic angiography, patients were randomized to receive either alteplase 100 mg in 3 h (19 patients), or placebo (17 patients). The mean interval between qualifying anginal episode and initial angiography was 10 and 9 h for the alteplase and placebo group, respectively. Angiography was repeated and angioplasty was performed within 24 hours. Between the first and the second angiogram, five patients in the alteplase and seven in the placebo group had recurrent ischaemic episodes, while four alteplase and three placebo patients showed signs of myocardial necrosis (creatine kinase (CK) rise greater than or equal to twice the upper limit for normal). Intracoronary clots were recognized in three alteplase patients and one placebo patient at the first angiogram, while two alteplase patients and one placebo patient showed total occlusion of the ischaemic-related vessel. After infusion, thrombi were present in four alteplase patients and one placebo patient, and total occlusion in three alteplase patients and one placebo patient. Quantitative coronary angiography showed no change in the percentage diameter stenosis of the ischaemia-related segment after drug infusion, (alteplase 67 +/- 16 to 69 +/- 16%; placebo 65 +/- 11 to 63 +/- 12%). Angioplasty was successful in 14 of 19 alteplase and 14 of 16 placebo patients.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, Erasmus University, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: van den Brand
authors.forename: A
authors.initials: A
authors.lastname: van Zijl
authors.forename: R
authors.initials: R
authors.lastname: Geuskens
authors.forename: P J
authors.initials: PJ
authors.lastname: de Feyter
authors.forename: P W
authors.initials: PW
authors.lastname: Serruys
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
mesh_terms: D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D003328:Coronary Thrombosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D003402:Creatine Kinase / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000201:enzymology / Q000209:etiology; D012008:Recurrence; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D003402:Creatine Kinase; D010959:Tissue Plasminogen Activator